Introduction {#s5}
============

Matrix metalloproteinases (MMPs) are zinc-dependent proteases that are involved not only in the degradation and remodeling of the extracellular matrix but also in processing bioactive molecules, including cell surface receptors, neurotrophic factors, chemokines, and cytokines ([@CIT0018]). Gelatinases, including MMP-9 and MMP-2, are similar in structure and can enzymatically process various substrates of the extracellular matrix. These enzymes are also known to be involved in pathological processes such as cancer, neurodegenerative disorders, arthritis, and cardiovascular diseases ([@CIT0026]). MMPs are involved in the pathogenesis of inflammatory diseases, including depression, as depression appears to be intimately linked to systemic inflammation ([@CIT0019]; [@CIT0002]). Several studies have reported an association between depressive symptoms and state-dependent elevation in levels of inflammatory cytokines, such as interleukin-1 β, interleuki-6, and tumor necrosis factor-α ([@CIT0008]; [@CIT0023]). Thus, inflammatory cytokine mediators, such as MMPs, could be pivotal in the clinical progression of depression ([@CIT0002]), which suggests that modulating these factors could lead to amelioration or remission of symptoms.

A previous study showed that there were significant associations between serum levels of MMPs and depressive symptoms ([@CIT0027]). Furthermore, serum levels of MMP-9 in depressive patients were decreased following a course of electroconvulsive therapy (ECT). Levels of MMP-2 in depressive patients were significantly lower than that of healthy controls, and low levels of MMP-2 were increased after a course of ECT ([@CIT0027]). The literature suggests that MMP-9 and MMP-2 could be related to depressive symptoms, and these symptoms appear to be sensitive to ECT.

ECT is a highly effective acute treatment for severe depressive symptoms ([@CIT0012]). However, there is a high rate of relapse of patients who respond to an acute course of ECT ([@CIT0017]; [@CIT0015]). The prevention of relapse is an important clinical issue, and clarification of potential predictors associated with relapse after ECT are needed. Some clinical factors that suggest likelihood to relapse following ECT have been suggested, including greater frequency of depressive episodes, symptom resistance to medication, residual symptoms, female gender, psychosis, and comorbid conditions ([@CIT0022]; [@CIT0020]). Biological markers, objective measures of physiological functioning, could be used to compare and contrast the efficacy of therapeutics. Potential biological markers that could be used to predict relapse after ECT, such as the dexamethasone suppression test, thyrotropin-releasing hormone stimulation, and rapid eye movement sleep latency, have been suggested, but all have, thus far, proven inconclusive ([@CIT0011]; [@CIT0005]). The current study proposes that peripheral inflammatory markers could be used to predict the potential for relapse after ECT. Serum levels of MMP-9 and MMP-2 were measured before and after ECT in depressed patients.

Methods {#s6}
=======

Subjects {#s7}
--------

The current study was a prospective study performed in a hospital setting at the Department of Psychiatry of the National Hospital Organization (NHO) Kure Medical Center. Data were collected between January 2011 and August 2016. Thirty-eight patients with depressive symptoms scheduled to receive acute ECT, based on eligibility guidelines of the American Psychiatric Association, participated in the study. Patients on maintenance ECT were not included in the current study. ECT is often prescribed when a patient exhibits episodes of severe major depression, psychosis, and catatonia or has shown insufficient improvement with prescribed pharmacotherapy ([@CIT0001]). The patients in the current study were diagnosed as having mood disorder, either a major depressive disorder or bipolar disorder, with a current episode of major depression according to the criteria of the DSM-IV-TR. No patient was diagnosed with either Axis I or Axis II disorders. Exclusion criteria were past or present history of substance abuse, substance dependence, significant neurological illness, or any other significant medical illness. After procedures were fully explained, written informed consent was obtained from all subjects prior to participation. The current study was approved by the Ethics Committee of NHO Kure Medical Center.

The current study employed 2 separate control groups for a total of 80 healthy volunteers. In control group 1, 40 healthy volunteers (14 men and 26 women, mean age±SD: 54.2±13.9 years) with no history or current mental disorder were recruited. While the volume of serum obtained from control group 1 was sufficient to assay for MMP-9, it was insufficient to assay for MMP-2. Thus, MMP-2 was measured from serum obtained from a second control group (control group 2) consisting of 40 healthy volunteers (17 men and 23 women: 57.6±12.9 years).

Clinical Assessments {#s8}
--------------------

Clinical symptoms were assessed using the 17-item Hamilton Rating Scale for Depression (HAMD) prior to the first ECT session (Pre-ECT) and the day after the final ECT session (Post-ECT) by the same psychiatrist. Responders to ECT were defined as demonstrating a 50% decrease in HAMD score.

Relapse was considered to have occurred when a patient had Clinical Global Impressions Improvement Scale scores≧6 after ECT and/or required hospitalization for exacerbation of psychiatric symptoms. After the acute course of ECT, all patients received standard pharmacotherapy, such as antidepressants or mood stabilizers, for major depressive disorder or bipolar disorder according to clinical guidelines of the Japanese Society of Mood Disorders.

ECT Treatment Procedures {#s9}
------------------------

ECT was performed according to previously established protocols ([@CIT0030]). Anesthesia was induced with i.v. thiamylal sodium and suxamethonium chloride. The ECT device used was the Thymatron System IV brief pulse square wave apparatus (Somatics Inc). Bilateral frontal-temporal electrodes were used, since the majority of patients demonstrated life-threatening or treatment-resistant depressive illness. Only one adequate seizure was required for each session, which was defined as an electroencephalographic seizure lasting more than 25 seconds with a high-amplitude, regular slow wave and postictal suppression. According to American Psychiatric Association guidelines, responsiveness to treatment was based on changes in the targeted symptoms. While the typical ECT course in patients with major depression is between 6 and 12 treatments, some patients manifest complete remission after only a few treatments ([@CIT0001]). We continued ECT until the patient was asymptomatic or the primary care psychiatrist determined that the patient had obtained the maximum benefit within 3 to 15 sessions.

Antidepressant and antipsychotic pharmacotherapy received before ECT were continued in principle during ECT. The clinical psychiatrist could change the type and dosage of their medication on a case-by-case basis. Mood stabilizers were withdrawn prior to the first ECT session but restarted after ECT. The use of benzodiazepines was permitted during the study period. Patients underwent standard supportive psychotherapy during the study period.

MMP Assay {#s10}
---------

Venous blood samples were taken during the morning (between 7:00 and 8:00 [am]{.smallcaps}) before the first ECT session (Pre-ECT) and the day after the final ECT session (Post-ECT). From healthy controls, blood samples were collected only once. Blood samples were drawn into anticoagulant-free tubes, kept at room temperature for 1 h, and serum was separated by centrifugation at 3000 rpm for 15 minutes at 4°C. Serum samples were stored at −80°C until assay. Serum levels of MMP-2 and MMP-9 were measured using ELISA (Quantikine ELISA, R&D Systems) according to the manufacturer's instructions.

Statistical Analysis {#s11}
--------------------

The data are shown as the mean±SD. The normal distribution of data was tested by Shapiro-Wilk and the Kolmogorov-Smirnov tests ([supplementary Table 1](#sup1){ref-type="supplementary-material"}), and statistical analysis was performed with nonparametric tests. The Mann-Whitney *U* test was used to determine significant differences among groups in clinical and laboratory values. A chi-squared test was used for categorical variables. The Wilcoxon signed-rank test was used to determine whether differences in clinical and laboratory values between Pre-ECT and Post-ECT were significant. Statistical significance was defined as *P*\<.05. Statistical analyses were performed using SPSS version 22.0 for Windows (IBM Japan Corporation).

Results {#s12}
=======

The final sample included 28 patients. Of the initial 38 patients, 10 were excluded for the following reasons: 3 patients did not recover from their depressive episode following ECT, 5 had moved from the area, and 2 patients were lost to follow-up. Among the remaining 28 patients (18 women and 10 men, mean age 59.6± 14.3 years) who were regularly followed for more than 1 year, 18 patients relapsed (64.3%) and the mean period to relapse was 21.2±12.3 weeks. Of these, 4 relapsed within 3 months, 9 between 3 and 6 months, and 5 between 6 months to 1 year after ECT.

The baseline clinical characteristics of the 28 patients who completed the study are shown in [Table 1](#T1){ref-type="table"}. Baseline characteristics were compared with relapsed and nonrelapsed patients, and there were no significant differences between the groups in terms of gender, age, age at onset, diagnosis of major depressive disorder or bipolar disorder, HAMD score, or number of ECT sessions.

###### 

Clinical Characteristic of Relapsed vs. Nonrelapsed Depressed Patients after ECT

  -----------------------------------------------------------------------
                                Relapsed         Nonrelapsed      
  ----------------------------- ---------------- ---------------- -------
  Gender                                                          .724

   Female                       12 (66.7%)       6 (60.0%)        

   Male                         6 (33.3%)        4 (40.0%)        

  Age (y)                       58.6 ± 12.8      61.4 ± 17.3      .549

  Age at onset (y)              49.9 ± 11.5      55.4 ± 20.2      .337

  Diagnosis                                                       .569

   Major depressive disorder    11 (61.1%)       5 (50.0%)        

   Bipolar disorder             7 (38.9%)        5 (50.0%)        

  HAMD score at Pre-ECT         21.7 ± 7.4       22.0 ± 8.5       .885

  HAMD score at Post-ECT        4.9 ± 1.8        3.9 ± 2.0        .115

  Reduction of HAMD score       16.8 ± 7.6       18.1 ± 8.6       .648

  Number of ECT (sessions)\     9.8 ± 3.2\       10.2 ± 1.8\      .825\
  IMI equivalence at Pre-ECT\   163.2 ± 109.3\   153.8 ± 149.1\   .869\
  IMI equivalence at Post-ECT   153.5 ± 90.9     108.8 ± 150.5    .175
  -----------------------------------------------------------------------

Abbreviations: ECT, electroconvulsive therapy; HAMD, Hamilton Rating Score for depression; IMI, imipramine.

Data show the mean ± SD or percent (%).

*P* values of the chi-square test and the Mann-Whitney *U* test are reported.

Levels of serum MMP-9 were compared between patients before ECT and healthy controls from control group 1. There was no significant difference in mean serum MMP-9 levels between the patients at Pre-ECT and healthy controls (537.1±244.5 ng/mL vs 481.5±216.9 ng/mL, *P*=.334). Over the course of ECT, a statistically significant decrease in serum MMP-9 (415.5±162.8 ng/mL at Post-ECT, *P*=.008) was observed in these patients.

Levels of serum MMP-2 were compared between patients before ECT and healthy controls from control group 2. The mean serum MMP-2 level of patients before ECT was significantly lower than that of healthy controls (186.1±36.1 ng/mL vs 235.5±56.8 ng/mL, *P*\<.001). There was a tendency of increased serum MMP-2 over the course of ECT in patients (206.3±53.3 ng/mL Post-ECT, *P*=.055). Additionally, serum levels of MMPs were not significantly different between patients with major depressive disorder and bipolar disorder ([supplementary Table 2](#sup1){ref-type="supplementary-material"}).

While patients who relapsed showed decreased mean serum MMP-9, the decrease was less than that of the group that did not relapse (relapse group =-60.7±174.1 ng/mL; nonrelapse group =-213.3±215.1 ng/mL; *P*=.021, see [Table 2](#T2){ref-type="table"}). In patients who relapsed, mean serum MMP-9 did not change during the course of ECT (Pre-ECT vs Post-ECT, *P*=.327). However, mean serum MMP-9 significantly decreased over the course of ECT treatment in patients who did not relapse (*P*=.007, [supplementary Figure 1](#sup1){ref-type="supplementary-material"}). There were no significant differences in mean serum levels of MMP-9 between the 2 groups of patients at Pre-ECT or Post-ECT. Mean serum levels of MMP-2 at Pre-ECT and Post-ECT were not significantly different, and the magnitude of change of serum MMP-2 over the course of treatment was not significantly different between patients who relapsed and patients who did not relapse ([Table 2](#T2){ref-type="table"}).

###### 

Serum Levels of MMP-9 and MMP-2 of Relapsed and Nonrelapsed Depressed Patients after ECT

                                                  Relapsed             Nonrelapsed          Control         
  ----------------------------------------------- -------------------- -------------------- --------------- -----------
  MMP-9 (ng/mlL)                                                                                            
   At Pre-ECT or baseline                         513.5 ± 241.5 ^ns^   579.5 ± 257.1 \*\*   481.5 ± 216.9   .424^b^
   At Post-ECT                                    \[452.8 ± 158.1\]    \[348.2 ± 156.3\]                    .093^a^
   Magnitude of change from Pre-ECT to Post-ECT   -60.7 ± 174.1        -231.3 ± 215.1                       .021^a^\*
  MMP-2 (ng/mL)                                                                                             
   At Pre-ECT or baseline                         185.4 ± 39.0         187.5 ± 32.1         235.5 ± 56.8    .001^b^
   At Post-ECT                                    207.4 ± 62.5         204.5 ± 33.8                         .415^a^
   Magnitude of change from Pre-ECT to Post-ECT   22.0 ± 52.9          17.0 ± 35.4                          .811^a^

Abbreviation: ECT, electroconvulsive therapy; ns, not significant.

Data show the mean ± SD.

^*a*^ *P* values of the Mann-Whitney *U* test.

^*b*^ *P* values of Kruskal-Wallis test and Wilcoxon signed-rank test are reported.

\**P*\<0.05, \*\**P*\<0.01.

Discussion {#s13}
==========

A previous study showed that circulating levels of MMP-9 in depressed patients are different compared with that of healthy controls ([@CIT0006]; [@CIT0003]), and a positive correlation was observed between serum levels of MMP-9 and HAMD scores ([@CIT0029]; [@CIT0027]). The current study confirms previous findings that serum levels of MMP-9 declined during ECT ([@CIT0027]) and further demonstrates an association between serum levels of MMPs and a higher risk of relapse after a course of ECT in depressed patients. In the current study, depressed patients who did not relapse showed significantly decreased Post-ECT MMP-9 serum levels compared with Pre-ECT levels. By contrast, in patients who relapsed, Post-ECT serum levels of MMP-9 were not significantly altered compared with Pre-ECT levels. The current findings suggest that MMP-9 levels could be used as an indicator of the likelihood of relapse in depressed patients after successful ECT.

The mechanism by which ECT reduces serum levels of MMP-9 is unknown. A state of systemic inflammation has been proposed as the substrate of mood disorders, since circulating proinflammatory cytokines increase with the severity of mood disorders ([@CIT0008]; [@CIT0023]) and cytokine levels decrease after an effective course of ECT ([@CIT0013]; [@CIT0024]). It is possible that the abnormal inflammatory state in depressed patients is normalized through ECT treatment ([@CIT0027]). Knockout of the MMP-9 gene reduced dendritic spine abnormalities and improved anxiety-related symptoms and poor socialization in a mouse psychiatric disorder model ([@CIT0028]). Minocycline, which has inhibitory effects on MMP-9, decreased MMP-9 levels and appeared to attenuate clinical symptoms of psychiatric disorder ([@CIT0007]). Degradation of MMP-9 could improve depressive symptoms and suppress relapse by "calming" of the inflammatory state. Indirect support of this hypothesis is the finding that inflammatory cytokines, interleukin-1αand monocyte chemoattractant protein-1, are associated with depression relapse within a year ([@CIT0004]). In the current study, the difference in serum levels of MMP-9 between Pre-ECT and Post-ECT was significantly associated with the likelihood of relapse, rather than MMP-9 levels at either Pre-ECT or Post-ECT. An association may not be readily discernable at a given MMP-9 level, since MMP-9 levels have been shown to change in healthy subject for a variety of reasons, including psychosocial stress ([@CIT0009]). Further large-scale studies are needed to confirm whether alterations of MMP-9 serum levels can be used as a predictor of relapse in depressed patients.

During the 1-year follow-up period in the current study, 18 (64%) of the 28 treatment responders to ECT experienced a relapse. A recent meta-analysis of prospective studies in major depressive patients treated with ECT showed that the relapse rate after 12 months was 51.1% ([@CIT0016]). A relapse rate of about 50% within 12 months during a mean follow-up period of 55.3 weeks with continuous pharmacotherapy for bipolar depression after a course of ECT has also been reported ([@CIT0020]). Although previous results cannot be directly compared with each other because the definition of relapse and the severity of symptoms differ, the high relapse rate after responding to ECT for depressive symptom is a considerable problem. Therefore, finding a predictor of relapse after ECT will greatly aid in designing effective treatments for all depressed patients.

The current study focused on uncovering an association between MMPs and relapse following ECT in depressed patients. It is not known whether reduced levels of MMPs are observed after relapse with other treatments, such as pharmacotherapy and cognitive behavioral therapy. It would be important to determine if MMP-9 levels are associated with relapse in depressed patients after other types of treatments to see if altered MMP levels can be used as a general indicator of likelihood to relapse.

Some limitations of the current study should be mentioned. First, the relatively small sample size hampered identification of a significant association of MMP-9 levels and relapse. Second, the current study was designed as a naturalistic study. A variety of maintenance pharmacotherapies was allowed, because the medications were selected based on the clinical judgment of the attending psychiatrist and no attempt was made to standardize pharmacotherapeutic treatment. Third, other factors that could affect relapse rates, such as patient adherence to medication schedules, patient recognition of the severity of their own illness, adverse life events, level of social support, and premorbid psychosocial functioning were not collected. It is possible that these factors could somehow influence MMP levels---as mentioned earlier, MMP levels are modulated by a number of factors. Fourth, the effect of medications on serum MMPs levels is not well understood. In a past report, serum levels of MMP-9 in depressed patients with bipolar disorder were significantly higher than those of the controls, which remained elevated even following drug treatment ([@CIT0025]). ECT could have a greater influence on MMP-9 than medications. A future investigation could include drug-naïve patients to evaluate the effects of medications on MMP, at least before treatments. Fifth, it is unclear if peripheral concentrations of MMP reflect those in the brain. In an animal study, electroconvulsive seizure increases MMP-9 in the hippocampus ([@CIT0010]). There are some reports that found no correlation between blood and cerebrospinal fluid concentrations of MMPs ([@CIT0021]; [@CIT0014]). Therefore, it is possible that the dynamics of MMPs in the brain are different from those in peripheral tissues. To overcome this issue, direct assessment of MMPs in cerebrospinal fluid from patients with mood disorders could be highly useful. Finally, because of the limited sample size, statistically significant increases in MMP-2 levels were not observed following ECT in the current study, in contrast to a previous finding ([@CIT0027]). In any case, in the current study, MMP-2 was not associated with relapse after ECT. Larger studies in the future could investigate the occurrence of relapse after ECT in a more systematic manner and identify threshold levels of MMP-9 that best predict relapse following ECT.

Conclusion {#s14}
==========

The current study suggests that a greater magnitude in the decline of serum MMP-9 after ECT is related to a lower risk of relapse following ECT. The findings suggest that serum MMP-9 could be used to predict the likelihood of relapse following ECT in depressed patients.
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